Unique Genetic Characteristics and Clinical Prognosis of Female Patients with Lung Cancer Harboring RET Fusion Gene
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Unique Genetic Characteristics and Clinical Prognosis of Female Patients with Lung Cancer Harboring RET Fusion Gene
Authors
Keywords
-
Journal
Scientific Reports
Volume 10, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-06-25
DOI
10.1038/s41598-020-66883-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Phase I Study of Cabozantinib in Japanese Patients with Expansion Cohorts in Non-Small-Cell Lung Cancer
- (2019) Hiroshi Nokihara et al. Clinical Lung Cancer
- GDNF and the RET Receptor in Cancer: New Insights and Therapeutic Potential
- (2019) Lois M. Mulligan Frontiers in Physiology
- Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update
- (2019) Hélène Blons et al. Journal of Thoracic Disease
- Discovery Stories of RET Fusions in Lung Cancer: A Mini-Review
- (2019) Kengo Takeuchi Frontiers in Physiology
- Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy
- (2018) Y S Li et al. ANNALS OF ONCOLOGY
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-throughput sequencing reveals distinct genetic features and clinical implications of NSCLC with de novo and acquired EGFR T790M mutation
- (2018) Panwen Tian et al. LUNG CANCER
- Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer
- (2018) Yosuke Miura et al. Cancers
- Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
- (2017) Oliver Gautschi et al. JOURNAL OF CLINICAL ONCOLOGY
- A systematic and genome-wide correlation meta-analysis of PD-L1 expression and targetable NSCLC driver genes
- (2017) Jin Li et al. Journal of Thoracic Disease
- Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
- (2017) Kiyotaka Yoh et al. Lancet Respiratory Medicine
- Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboringRETrearrangement: a phase II clinical trial
- (2016) S.-H. Lee et al. ANNALS OF ONCOLOGY
- RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients
- (2016) Shumei Kato et al. CLINICAL CANCER RESEARCH
- Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
- (2016) Alexander Drilon et al. LANCET ONCOLOGY
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice
- (2015) Luís Felipe Campesato et al. Oncotarget
- RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis
- (2014) K Tsuta et al. BRITISH JOURNAL OF CANCER
- ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: A comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features
- (2014) Yunjian Pan et al. LUNG CANCER
- RETfusion gene: Translation to personalized lung cancer therapy
- (2013) Takashi Kohno et al. CANCER SCIENCE
- RETFusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer
- (2012) Rui Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- KIF5B-RET fusions in lung adenocarcinoma
- (2012) Takashi Kohno et al. NATURE MEDICINE
- RET, ROS1 and ALK fusions in lung cancer
- (2012) Kengo Takeuchi et al. NATURE MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation